PsychedelicNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Filing of Provisional Patent for Cannabinoid-Based Pain Treatment

Company: InMed Pharmaceuticals, Inc. (IMLFF)
Category: News

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, marking an important step toward protection of the company’s intellectual and commercial property. “There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” Dr. Sazzad Hossain, chief scientific officer of InMed and a co-inventor on the newly-filed patent, stated in the news release. “InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.” Notably, InMed’s research into the potential of non-THC cannabinoids in treating pain targets a growing need within the greater pain management market that’s been exacerbated by the recent increase in the number of prescriptions issued for highly addictive and potentially damaging opioid pain killers.

To view the full press release, visit http://cnw.fm/oj8fT

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.

More from PsychedelicNewsBreaks

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) PsychedelicNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. PNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled visibility, recognition and brand awareness. PNW is where news, content and information converge.

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/disclaimer/

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050